Please login to the form below
asthma
This page shows the latest asthma news and features for those working in and with pharma, biotech and healthcare.
Phase 3 trial of AstraZeneca and Avillion’s PT027 shows promise for asthma patients
It is estimated that around 176 million asthma exacerbations occur globally each year, which can prove fatal. ... growing body of evidence around the value of as-needed anti-inflammatory treatment in asthma and support PT027’s potential to transform
Latest news
-
Sanofi’s asthma treatment approved by European Commission
Dupixent is suitable for 6- to 11-year-old children who have severe asthma and type 2 inflammation. ... Dupixent significantly reduces asthma attacks, helps children breathe better and improves their health-related quality of life.”.
-
Sanofi and Regeneron announce positive phase 3 trial results for Dupixent
The data was presented at the 2022 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting and showed that patients treated with 300mg of Dupixent on a weekly basis experienced
-
Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results
of diseases, including dermatological diseases such as prurigo nodularis and atopic dermatitis, respiratory diseases such as asthma and CRSwNP, and gastrointestinal diseases such as eosinophilic esophagitis.”. ... Presently, Dupixent is approved in
-
FDA rejects Takeda’s Eohilia after delays
Dupixent is already approved in the US, Europe, Japan and other countries for specific patient populations with atopic dermatitis and asthma.
-
Tezspire approved in US for severe asthma
maintenance treatment for adults and children aged 12 years and with severe asthma. ... The approval of Tezspire is long-awaited positive news for the asthma community.
More from news
Approximately 70 fully matching, plus 501 partially matching documents found.
Latest Intelligence
-
Charting patient pathways with precision for better healthcare
In asthma it is down at around 50% and even in oncology the compliance figures are shocking.
-
Mapping patient pathways with a focus on patient-centricity: the role of medical education
Currently, we are developing MDT education in oncology, heart failure, diabetes, HIV and asthma.
-
Health For All
From clinical research to the diagnosis and management of everything from asthma to oncology, we see opportunities at every contact point to improve the experience of people and communities who are
-
Mapping at launch: it’s time to update the satnav
COPD. It has recently been approved by the FDA for asthma too, but our analysis focuses on UK performance.
-
On our best behaviour
Historically, asthma patients were responsible for recording their own symptoms and exacerbations, which can be difficult to remember over long periods. ... The Propeller platform has been shown to increase medication adherence by up to 58%, increase
More from intelligence
Approximately 3 fully matching, plus 51 partially matching documents found.
Latest appointments
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
inflammation test for managing asthma, across key markets such as the United States, China, and Japan, as well as the rest of the world.
-
Takeda UK & Ireland appoints market access director
company's first respiratory biologic for severe asthma.
-
Enterprise Therapeutics appoints CEO
In his new role, Dr Ford will oversee the development of the company's novel muco-regulatory therapies for patients suffering with chronic obstructive pulmonary disease, cystic fibrosis and severe asthma.
-
Former RBS head takes the reins as GSK chair
the past year, and to develop new products in order to offset the decline of its best-selling asthma drug, Advair, as part of his new remit.
-
GSK's Dr Brett Haumann takes up chief medical officer role at Circassia
Most recently these saw him serve as VP and medicines development leader responsible for the late-stage development of once-daily inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD).
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Article
Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma. ... Head of “Living With”, Mariel Metcalfe, discusses the nature of severe asthma and severe eosinophilic asthma, and some key findings from recent studies
-
Addressing Climate Impact: The Healthcare Paradox
Boehringer Ingelheim recently introduced the first reusable, propellant-free inhaler for patients with asthma and COPD, supporting objectives of carbon and plastic waste reduction.
-
How will the Tories’ historic win shape the NHS?
For example, with long term conditions such as asthma and diabetes, remote monitoring enables better self-management, which in turn, should lead to fewer hospital admissions, less face-to-face contact
-
Digital therapeutics and their impact on society
This is in part due to the explosive, bordering on unmanageable, increase in chronic diseases, such as cardiovascular disease, diabetes, Alzheimer’s disease, obesity and asthma.
-
Secrets of Pharma Advertising
Asthma ads look like asthma ads because that's what the audience expects.
More from PMHub
Approximately 3 fully matching, plus 20 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
-
Head of Health Psychology, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
-
Senior Health Psychologist, London
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
- Scientists discover new approach to treat brain tumours
- Recognising HIV Vaccine Awareness Day
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- Phase 3 trial of AstraZeneca and Avillion’s PT027 shows promise for asthma patients
- Live Webinar: The Future of MedTech: Streamlined Clinical Data Collection & Management
- Medscape: Connect to the conversation
- A Medscape 4-part video interview series
- Why big pharma needs to be braver
- MadMicrobe Studios Inc Announces New European Venture
- EMA accepts Valneva’s marketing authorisation application for COVID-19 vaccine
- BioXcel Therapeutics begins phase 3 trial for acute agitation in Alzheimer’s patients
- EMA accepts Valneva’s marketing authorisation application for COVID-19 vaccine
- FDA approves Bavarian Nordic’s smallpox and monkeypox vaccine
- Rare Disease Day – looking to the future with hope
- An effective commercial model for cancer care
- BMA appoints two internal candidates to share the role of chief executive officer
PMHub
Origins Insights
Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...
Latest intelligence
- Why big pharma needs to be braver
- The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
- Food Allergy – Is avoidance the only option?
- Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
